We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Laboratory Test Identifies Patients Infected With Swine Flu Virus

By LabMedica International staff writers
Posted on 27 May 2009
A laboratory test has been developed for identification of the virus that causes swine flu. More...


Swine flu is a respiratory disease that is caused by the H1N1 serotype of influenza A virus. The influenza A virus infects mainly humans, pigs, and birds. Scientists believe that the H1N1 subtype has mutated from a type that primarily infected pigs into a new form that is now transmissible through direct human-to-human contact.

Quest Diagnostics (Madison, NJ, USA), through its Focus Diagnostics (Cypress, CA, USA) infectious disease reference laboratory, has introduced a laboratory-developed RNA real-time polymerase chain reaction (PCR) test to aid in identifying novel swine flu virus infection.

Physicians can order the new Focus Diagnostics test to aid in the diagnosis of influenza A virus including the H1N1 serotype. It will be possible to submit patient specimens that are found to be positive for influenza A virus by a Quest Diagnostics' regional laboratory (or other clinical laboratory) to the Focus Diagnostics reference laboratory to determine whether the virus is the H1N1 serotype responsible for swine flu.

Quest Diagnostics provides different laboratory techniques including polymerase chain reaction (PCR), rapid cell culture, direct immunofluorescence (DFA), and enzyme immunoassay (EIA) testing. The Influenzavirus A testing services use specimens that include nasopharyngeal swabs, nasal secretions, nasal wash (lavage), and aspirations.

For more information on Swine flu and what you can do to minimize infection, see the U.S. Centers for Disease Control and Prevention's (CDC; Atlanta, GA, USA) web information on Swine Flu below.

Related Links:

Quest Diagnostics
Focus Diagnostics
U.S. Centers for Disease Control and Prevention
Web information on Swine Flu



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.